stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
35.00
2.47
+7.59%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) EBITDA
Pharvaris N.V.'s EBITDA for fiscal 2025 was −$191.7M, compared with −$157.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$212.2M. Over the past ten years it has ranged from −$191.7M (fiscal 2025) to −$5.1M (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 7 consecutive fiscal years. Pharvaris N.V. ranks 517th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$191.7M | — |
| FY2024 | −$157.4M | — |
| FY2023 | −$104.6M | — |
| FY2022 | −$91.2M | — |
| FY2021 | −$64.0M | — |
| FY2020 | −$28.6M | — |
| FY2019 | −$9.0M | — |
| FY2018 | −$5.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$58.8M | — |
| Mar 2026 | −$51.7M | — |
| Dec 2025 | −$55.4M | — |
| Sep 2025 | −$46.2M | — |
| 19 more quarters | Free account |
Against its own ten years
Low −$191.7M
High −$5.1M
Ten-year median
−$77.6M
Current reading's percentile
13
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| PHVS Pharvaris N.V. | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item